Eli Lilly and Company (NEO:LLY)

Market Cap	924.74B
Revenue (ttm)	70.43B
Net Income (ttm)	15.96B
Shares Out	n/a
EPS (ttm)	17.66
PE Ratio	57.93
Forward PE	29.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,212
Average Volume	54,609
Open	28.44
Previous Close	28.25
Day's Range	27.75 - 28.44
52-Week Range	25.15 - 36.42
Beta	0.39
RSI	51.40
Earnings Date	Aug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD